Skip to main content

Table 1 Baseline characteristics of healthy controls and IPF patients

From: Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis – a potential biomarker role for LysoPC

 

Pilot study

 

Validation study

 
 

Healthy

IPF

Healthy

IPF

Subjects (male %)

10 (90)

10 (90)

10 (60)

11 (82)

Age (years)

68.7 ± 7.9

67.8 ± 8.6

32.4 ± 15.3

66.1 ± 8.6

BMI kg/m2

28.9 ± 5.1

26.9 ± 3.6

22.6 ± 2.7

26.3 ± 4.3

BMI ≥ 25 kg/m2

7

5

2

6

Diabetes mellitus type 2 (n)

1

2

0

3

Hypertension

5

5

0

3

Lung function

 FVC, L

4.1 ± 0.4

2.4 ± 0.5

4.5 ± 1.0

2.4 ± 0.6

 FVC (% predicted)

114.6 ± 8.5

65.1 ± 11.3

94.0 ± 10.3

63.1 ± 14.3

 DLCO (% predicted)

129.6 ± 31.1

43 ± 15.0

87.8 ± 11.3

44.6 ± 14.6

 GAP Stage (I-III)

I - II

I- II

Smoking status

 Current Smokers n (median pack years ± SD)

0

0

5 (8.2 ± 14.5)

0

 Former Smokers n (median pack years ± SD)

8 (5.5 ± 5.7)

8 (25.4 ± 15.2)

0

8 (13.9 ± 13.3)

Antifibrotic therapy

 Pirfenidone n (%)

6 (60)

6 (54.5)

 Nintedanib n (%)

3 (30)

4 (36.4)

 No antifibrotics n (%)

1 (10)

1 (9.1)

  1. FVC Forced vital capacity, DLCO Diffusing capacity of the lung for carbon monoxide, BMI Body Mass Index